间充质干细胞来源的外泌体通过miR-132-3p/PTEN/AKT途径改善心肌缺血/再灌注损伤中的葡萄糖代谢受损。
Exosomes derived from mesenchymal stem cells ameliorate impaired glucose metabolism in myocardial Ischemia/reperfusion injury through miR-132-3p/PTEN/AKT pathway.
作者信息
Wu Hongkun, Hui Yongpeng, Qian Xingkai, Wang Xueting, Xu Jianwei, Wang Feng, Pan Sisi, Chen Kaiyuan, Liu Zhou, Gao Weilong, Bai Jue, Liang Guiyou
机构信息
School of basic Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
Center for Translational Medicine, Guizhou Medical University, Guiyang, Guizhou, China.
出版信息
Cell Cycle. 2024 Sep-Oct;23(17-20):893-912. doi: 10.1080/15384101.2025.2485834. Epub 2025 Apr 3.
Exosomes secreted by mesenchymal stem cells (MSCs) have been considered as a novel biological therapy for myocardial ischemia/reperfusion injury (MIRI). However, the underlying mechanism of exosomes has not been completely established, especially in the early stage of MIRI. In this study, we primarily investigated the protective effect of exosomes on MIRI from both in vitro and ex vivo perspectives. Bioinformatic analysis was conducted to identify exosomal miRNA associated with myocardial protection, Genes and proteins related to functional studies and myocardial energy metabolism were analyzed and evaluated using techniques such as Polymerase Chain Re-action (PCR), Western blotting, double luciferase biochemical techniques, flow cytometry assay, etc. It was discovered that exosomes ameliorated cardiomyocyte injury t by delivery of miR-132-3p.This process reduced the expression of Phosphatase and tensin homolog (PTEN) mRNA and protein, enhanced the expression of phosphorylated protein kinase (pAKT), regulated the insulin signaling pathway, facilitated intracellular Glucose transporter 4 (GLUT4) protein membrane translocation, and enhanced glucose uptake and Adenosine Triphosphate (ATP) production. This study confirmed, for the first time, that MSC-EXO can provide myocardial protection in the early stages of MIRI through miR-132/PTEN/AKT pathway. This research establishes a theoretical and experimental foundation for the clinical application of MSC-derived exosomes.
间充质干细胞(MSCs)分泌的外泌体已被视为一种治疗心肌缺血/再灌注损伤(MIRI)的新型生物疗法。然而,外泌体的潜在机制尚未完全明确,尤其是在MIRI的早期阶段。在本研究中,我们主要从体外和体内两个角度研究了外泌体对MIRI的保护作用。通过生物信息学分析来鉴定与心肌保护相关的外泌体miRNA,使用聚合酶链反应(PCR)、蛋白质免疫印迹法、双荧光素酶生化技术、流式细胞术检测等技术对与功能研究和心肌能量代谢相关的基因和蛋白质进行分析和评估。研究发现,外泌体通过递送miR-132-3p改善了心肌细胞损伤。这一过程降低了磷酸酶和张力蛋白同源物(PTEN)mRNA和蛋白质的表达,增强了磷酸化蛋白激酶(pAKT)的表达,调节了胰岛素信号通路,促进了细胞内葡萄糖转运蛋白4(GLUT4)蛋白向细胞膜的转位,并增强了葡萄糖摄取和三磷酸腺苷(ATP)生成。本研究首次证实,MSC-EXO可通过miR-132/PTEN/AKT途径在MIRI早期提供心肌保护。该研究为MSC来源的外泌体的临床应用奠定了理论和实验基础。